Zobrazeno 1 - 10 of 214 pro vyhledávání: '"C, Reenaers"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
P732 Impact of different types of physical activity in inflammatory bowel disease
Autor: A Gofflot, L Monin, L Seidel, C Reenaers, S Kropp, C Van Kemseke, P Latour, B Forthomme, J L Croisier, E Louis, S Vieujean
Publikováno v: Journal of Crohn's and Colitis. 17:i861-i862
Background Moderate physical activity (PA) appears to be beneficial for inflammatory bowel disease (IBD), improving the symptoms of the disease and promoting the maintenance of remission. However, little is known about the impact of different types o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b9dc0f6507ab3a8d7d69692ff881f6a
https://doi.org/10.1093/ecco-jcc/jjac190.0862
Zobrazit plný text záznamu
5
[Advances in the management of inflammatory bowel diseases]
Autor: C, Reenaers, E, Louis
Publikováno v: Revue medicale de Liege. 77(5-6)
New therapeutic strategies and new molecules have been recently developed for the management of inflammatory bowel diseases. The treat-to-target strategy aims to define specific objectives based on the patient and the disease characteristics. A regul
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::deb0d1319df1c47827a40813aab35329
https://pubmed.ncbi.nlm.nih.gov/35657190
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Essential reading from the editor’s desk
Autor: C Reenaers, Tim Vanuytsel
Publikováno v: Acta Gastro Enterologica Belgica. 85:431-432
The prevalence of metabolic dysfunction associated liver disease (MALFD) – previously known as non- alcoholic fatty liver disease (NAFLD) – has increased dramatically in the past few decades and is now the most common cause of chronic liver disea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dadb44527efb52d65e6474c44b6aab97
https://doi.org/10.51821/85.3.11044
Zobrazit plný text záznamu
8
P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
Autor: G Le Cosquer, C Gilletta, A Amiot, P Rivière, M Nachury, C Rouillon, Y Bouhnik, V Abitbol, S Nancey, M Fumery, G Savoye, A Biron, L Picon, L Peyrin-Biroulet, M Vidon, C Reenaers, M Simon, B Caron, M Serrero, R Altwegg, A Benezech, F Goutorbe, J F Rahier, L Beaugerie, A L Pelletier, L Caillo, D Laharie, F Poullenot
Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Background Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD) unrelated to the disease or its treatment (Poullenot F et al. JCC 2022). The main aim of our study was to assess the risk of incident c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a58a414d1b5237c1930c6c7670ed2eb
https://doi.org/10.1093/ecco-jcc/jjac190.0573
Zobrazit plný text záznamu
9
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study
Autor: C Cottron, X Treton, R Altwegg, C Reenaers, A Amiot, M Fumery, L Vuitton, L Peyrin-Biroulet, G Bouguen, O Dewit, S Nancey, L Caillo, X Roblin, M Beylot-Barry, P Rivière, D Laharie
Publikováno v: Journal of Crohn'scolitis. 16(8)
Background and Aims Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evoluti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51a19303dcea0e37e1d4e477cd9778e6
https://pubmed.ncbi.nlm.nih.gov/35218189
Zobrazit plný text záznamu
10
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
Autor: F Poullenot, A Amiot, M Nachury, S Viennot, R Altwegg, Y Bouhnik, V Abitbol, S Nancey, L Vuitton, L Peyrin-Biroulet, A Biron, M Fumery, L Picon, M Vidon, C Reenaers, M Serrero, G Savoye, L Beaugerie, P Rivière, D Laharie
Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f22cc6a4e0b0eee459214fd8327e50
https://pubmed.ncbi.nlm.nih.gov/35512337
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje